Rapport Therapeutics
RAPP
144 hedge funds and large institutions have $1.55B invested in Rapport Therapeutics in 2025 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 51 increasing their positions, 30 reducing their positions, and 20 closing their positions.
100% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 20
70% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 30
61% more call options, than puts
Call options by funds: $834K | Put options by funds: $519K
16% more funds holding
Funds holding: 124 → 144 (+20)
6% more capital invested
Capital invested by funds: $1.46B → $1.55B (+$86.4M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
27.83% less ownership
Funds ownership: 135.01% → 107.18% (-28%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$23.9M |
| 2 |
Goldman Sachs
New York
|
+$16M |
| 3 |
State Street
Boston,
Massachusetts
|
+$9.5M |
| 4 |
PA
Perceptive Advisors
New York
|
+$7.47M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$7.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$9.55M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$9.18M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$8.3M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$7.44M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.11M |
RAPP Hedge Fund Activity: Q4 2025 in Review
144 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Rapport Therapeutics (RAPP) for Q4 2025, worth a combined $1.55B — up 5.9% from $1.46B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new RAPP positions and 20 closed out — a net gain of 20 holders — while 51 added to existing stakes and 30 trimmed.
The largest buyer was BlackRock, adding an estimated $23.9M. The largest seller was Siren LLC, cutting an estimated $9.55M.
- 144 institutional investors held Rapport Therapeutics (RAPP) as of Q4 2025, up from 124 in Q3 2025.
- Funds reported $1.55B of Rapport Therapeutics stock for Q4 2025, up 5.9% quarter-over-quarter.
- 40 funds opened new Rapport Therapeutics positions in Q4 2025 and 20 closed out, a net change of +20 holders.
- The largest Rapport Therapeutics buyer in Q4 2025 was BlackRock, an estimated $23.9M added.
- The largest Rapport Therapeutics seller in Q4 2025 was Siren LLC, an estimated $9.55M sold.
Based on aggregated 13F filings for Q4 2025.